非水电位滴定法测定盐酸莫雷西嗪原料的含量

目的建立革除汞盐的非水电位滴定法测定盐酸莫雷西嗪原料的含量。方法建立以冰醋酸与醋酐（1：3）为溶剂的高氯酸非水电位滴定法测定盐酸莫雷西嗪原料的含量。结果与2005年版《中国药典（二部）》方法测定结果一致。结论该法操作简单,灵敏度高,准确可靠,重复性及稳定性良好,适于盐酸莫雷西嗪原料的含量测定。     

高效液相色谱法测定复方地塞米松庆大霉素滴鼻液中两组分含量

目的探讨用高效液相色谱法（HPLC法）同时测定复方地塞米松庆大霉素滴鼻液中盐酸麻黄素和地塞米松磷酸钠的含量。方法采用美国Waters高效液相色谱仪，流动相为甲醇-0．1mol／L醋酸铵溶液（50：50，用磷酸调pH值至4．0），流速为1．0mL／min，检测波长为256nm。结果盐酸麻黄碱和地塞米松磷酸钠在此条件下可实现基线分离，两组分质量浓度线性范围分别为50—500μg／mL（r=0．9995）和3．5～35μg／mL（r=0．9994），平均回收率分别为99．5％（RSD=0．8％）和99．4％（RSD=1．3％）。结论HPLC法简便快速，准确可靠，可作为复方地塞米松庆大霉素滴鼻液的质量控制方法。     

Moricizine Induced Increase in Pacing Threshold

GIROD, J.P., et al. : Moricizine Induced Increase in Pacing Threshold. A 72-year-old woman who was experiencing incessant ventricular tachycardia and recurrent automatic implantable cardioverter defibrillator (AICD) firing despite amiodarone therapy was referred to the Cleveland Clinic Foundation. Myocardial ischemia and infarction were ruled out by standard means. Several antiarrhythmic medications were tried previously without success. Moricizine, 200 mg three times daily, was initiated and controlled the ventricular tachycardia. However, after the dose of moricizine was titrated upward, the patient became symptomatically bradycardic and the ECG exhibited 2:1 block of her paced rhythm and an increased ventricular pacing threshold. (PACE 2003; 26[Pt. I]:110–111)     

国产莫雷西嗪抑制电诱发折返性室上性心动过速及其临床意义

１７例折返性室上性心动过速（ＲＳＶＴ）口服莫雷西嗪６００ｍｇ／ｄ后，经食管心房调搏证实：该药对ＲＳＶＴ电诱发的总抑制率为８８．２％（１５／１７例）。１例出现至心律失常作用；非心源性副作用轻微，发生率低。结果提示，莫雷西嗪可试用于预防ＲＳＶＴ的发作。     

Cardioversion, Defibrillation, and Overdrive Pacing of Ventricular Arrhythmias: The Effect of Moricizine in Dogs with Sustained Monomorphic Ventricular Tachycardia

The purpose of this investigation is to define whether the antiarrhythmic drug moricizine has beneficial or adverse effects on currently used antitachycardia and antifibrillatory devices. These studies were performed in a dog model of sustained monomorphic ventricular tachycardia (VT). In 11 dogs, the left anterior descending artery and all surrounding epicardial collateral feeder vessels were ligated. Defibrillator patches were implanted and the dogs were allowed to recover. After a 7-day recovery period, effective refractory period (ERP), end diastolic threshold (EDT), VT induction, and VT and ventricular fibrillation (VF) termination data were collected before and after moricizine infusion (2 mg/kg). In this experimental model, moricizine caused the folIowing electrophysiological changes: a prolongation of the ERP from 173 ± 14 to 182 ± 15 fP < 0.02) with no significant effect on the EDT for pacing; a prolongation of the VT cycle length from 175 ± 18 to 201 ± 23 msec (P < 0.003); an increased cycle length required for overdrive pacing from 136 ± 20 to 157 ± 22 msec (P < 0.01); no effect on the energy required to cardiovert VT; an increase in the defibrillation threshold from 7.5 ±4 to 9.4 ± 4 joules (P < 0.006) and; in 5 of the 8 dogs with VT, theVT could be initiated with somewhat less aggressive stimulation. Significant beneficial electrophysiological effects were noted on theVT cycle length, including a proportionately prolonged overdrive pacing cycle length for VT termination. These changes were contrasted by the significant increase in the VF conversion energy required and the ease with which the VT could be induced postmoricizine. These findings suggest a possible proarrhythmic effect of moricizine.     

罂粟壳中生物碱类化合物的含量测定

建立了以盐酸罂粟碱为对照品，以酸性染料比色法测定罂粟壳中生物碱类化合物的方法，此方法操作简单，灵敏度高，专属性强。     

盐酸川芎嗪氯化钠注射液的制备及稳定性研究

采用二次过滤法制备盐酸川芎嗪氯化钠注射液,紫外分光光度法测定其含量,三批样品含量分别为99.30％,102.55%,100.93％,平均回收率为100．25％（RSD＝0.36%)。建立了气相色谱法测定有关物质,并进行光照、高温、室温留样等稳定性研究,结果表明该注射液稳定性好,暂定有效期为二年。     

盐酸莫雷西嗪片剂人体生物等效性研究

 目的评价两种盐酸莫雷西嗪片剂的生物等效性。方法18名健康男性志愿者分别单剂量po受试制剂和参比制剂200mg,采用高效液相色谱-质谱联用法测定血浆中莫雷西嗪的浓度。结果受试制剂和参比制剂在受试者体内的药动学参数如下:血浆中莫雷西嗪的t_max分别为(1.4±0.4)和(1.4±0.5)h,ρ_max分别为(595±318)和(589±283)μg·L^-1,t_1/2分别为(2.4±0.9)和(2.7±1.5)h,用梯形法计算,AUC_0-t分别为(1.60±0.89)和(1.57±0.76)mg.h·L^-1,AUC_0-∞分别为(1.66±0.90)和(1.63±0.76)mg.h·L^-1,以AUC_0-t计算,莫雷西嗪的相对生物利用度平均为(103.6±28.8)%。结论两种制剂生物等效。     

莫雷西嗪预防近期阵发性心房颤动的随机对照研究

目的：开放随机对照观察莫雷西嗪在预防近期阵发性房颤（AF）发作的临床疗效。方法；103例近期起病的阵发性心房颤动（房颤）患（病程≤7天），入选时无器质性心脏病或有高血压但不伴心力衰竭。患随机分为三组：安慰剂组30例，莫雷西嗪组36例，普罗帕酮组37例，口服剂量均为600mg/d。观察2周，对初始药物预防无效患交叉用药，Ⅱ组11例莫雷西嗪治疗无效改服普罗帕酮；Ⅲ组20例普罗帕酮治疗无效改服莫雷西嗪。结果：（1）72小时内未出现房颤，莫雷西嗪组24例（66．7％），明显高于普罗帕酮组的14例（37．8％）（P＜0．01）；安慰剂组仅5例（16．7％）。（2）3天后至2周内未出现房颤，莫雷西嗪组25例（69．4％），普罗帕酮组22例（59．5％）（P＞0．05）；安慰剂组仅6例（16．7％）。（3）初始药物治疗2周无效患，Ⅱ组和Ⅲ组交叉用药3周。2周后未出现房颤，改服普罗帕酮的Ⅱ组5例（45．5％）；改服莫雷西嗪的Ⅲ组11例（55．0％）（P＞0．05）；安慰剂组仅6例（16．7％）。结论：口服莫雷西嗪能有效预防近期阵发性房颤的发作，3天内效果明显优于口服普罗帕酮600mg/d，3天后至4周两组间无明显差异，但均显优于安慰剂组。莫雷西嗪给药方便，副作用少，患可在门诊接受治疗。     

HPLC-ELSD法测定盐酸大观霉素的含量

目的：建立HPLC—ELSD方法测定盐酸大观霉素的含量。方法：以Grace—Apollo C18（150mm×4．6mm,5μm）为色谱柱,50mmol.L^1乙酸铵溶液（pH7．5）-甲醇（92：8）为流动相,流速为0．6ml·min～,雾化室温度：30oC,漂移管温度：70℃。雾化气体（空气）压力：0．4Mpa。结果：盐酸大观霉素在0．101～0．504mg·ml。范围内,呈良好的线性关系（r=0．9990）,平均回收率为98．5％（RSD=1．6％,12=9）。结论：该方法操作简便、快速,结果准确可靠,可应用于盐酸大观霉素的含量测定。